The significant medicine by Novartis named Canakinumab plus standard of care failed to bring about a greater chance of recovery in COVID-19 patients without...
January 24, 2021
The significant medicine by Novartis named Canakinumab plus standard of care failed to bring about a greater chance of recovery in COVID-19 patients without...
